• Home
    • Leucémie myéloïde chronique
    • Leucemia Mieloide Crónica
  • CML Experts
    • Team of experts on CML who developed imatinib >
      • Dr. Elisabeth Buchdunger
      • Dr. Brian Druker
      • Dr. John Goldman
      • Dr. Carlo Gambacorti-Passerini
      • Dr. Nora C. Heisterkamp
      • Dr. David Hungerford
      • Dr. Nicholas Lydon
      • Dr. Alex Matter
      • Dr. Felix Mitelman
      • Dr. Peter C. Nowell
      • Dr. Moshe Talpaz
      • Dr. Janet D. Rowley
      • Dr. Charles Sawyers
      • Dr. Jürg Zimmermann
      • Dr. Owen Witte
    • Experts involved in developing dasatinib >
      • Dr. Jagabandhu Das
    • Experts involved in developing nilotinib
    • Other CML experts in America >
      • Other CML experts in Canada >
        • Dr. Sarit Assouline
        • Dr. Lambert Busque
        • Dr. Robert Delage
        • Dr. Connies Eaves
        • Dr. Josée Hébert
        • Dr. Luigina Mollica
        • Dr. Dennis Kim
        • Dr. Pierre Laneuville
        • Dr. Conrad Vincent Fernandez
        • Dr. Isabelle Bence-Bruckler
        • Dr. Jeffrey H Lipton
        • Dr. Mark Hnatiuk
      • Other CML experts in US >
        • Carolyn Blasdel, RN , FNP-BC, OCN
        • Rey Garcia, RN, BSN
        • PATRICIA JAKEL, RN, MN, AOCN
        • Dr. Ravi Bhatia
        • Dr. Jorge E. Cortes
        • Dr. Javier Pinilla-Ibarz
        • Dr. Catriona Jamieson
        • Dr. Arul Chinnaiyan
        • Dr. Michael Deininger
        • Dr. James D. Griffin
        • Dr. Franziska Michor
        • Dr. Frank Giles
        • Dr. Gabriella Hobbs
        • Dr. Elias J. Jabbour
        • Dr. Hagop Kantarjian
        • Dr. Harry P. Erba
        • Dr. Richard A. Larson
        • Dr. Alison Loren
        • Dr. Michael Mauro
        • Dr. Matt Kalaycio
        • Dr. Stephen D. Nimer
        • Dr. Ruben A. Mesa
        • Dr. Susan M. O'Brien
        • Dr. Jerald P. Radich
        • Dr. Ellen K. Ritchie
        • Dr. Karen Seiter
        • Dr. Kendra Sweet
        • Dr. Neil Shah
        • Dr. Richard T Silver
        • Dr. Richard Stone
        • Dr. Raoul Tibes
        • Dr. Sangmin Lee
        • Dr. Bin Zhang
      • Other CML experts in South America >
        • Dr. Michele Bianchini
        • Dra Beatriz Moiraghi
        • Dra. Carla Boquimpani
        • Dr Carolina Pavlovsky
    • Other CML Experts in Europe >
      • CML Expert in Belgium >
        • Pr Gregor Verhoef
      • CML expert in France >
        • Dr. François-Xavier Mahon
        • Dr Aude Charbonnier
        • Dr. Delphine Rea
        • Dr. Gabriel Etienne
        • Dr. Lawrence Legros
        • Dr. Marie-Joëlle Mozziconacci
        • Pr. Mauricette Michallet
        • Dr. François Guilhot
        • Dr Françoise Huguet
        • Dr. Stéphane Prost
        • Dr. Philippe Rousselot
        • Dr. Eliane Gluckman
        • Dr. Franck-Emmanuel Nicolini
      • CML expert in Italy >
        • Dr. Chiara Elena
        • Dr. Michele Baccarani
        • Dr. Giuseppe Saglio
      • CML expert in UK >
        • Dr. Jane Apperley
        • Dr. Stephen O'Brien
        • Dr. Georgios Nteliopoulos
        • Dr. Adam Mead
        • Dr. Tessa L Holyoake
      • CML expert in Germany >
        • Dr. Andreas Hochhaus
        • Dr Susanne Saussele
        • Dr. Martin Müller
      • CML expert in Portugal >
        • Dr. Antônio Medina de Almeida
      • CML expert in Spain >
        • Dr. Juan Luis Steegmann
      • CML expert in Netherlands >
        • Dr. Jeroen J.W.M. Janssen
      • CML expert in Sweden >
        • Dr. Johan Richter
      • CML expert in Czech Republic >
        • Dr. Hana Klamova
    • Other CML experts in Asia >
      • Dr. Charles Chuah
      • Dr. Goh Yeow Tee
      • Dr. Pankaj Malhotra
      • Dr. Uday Yanamandra
      • Dr. Hemant Malhotra
      • Dr. Kim Dong-Wook
    • Other CML experts in Africa >
      • Dr. Anthony Oyekunle
    • Other CML experts in Australia >
      • Dr. Ilaria Pagani
      • Dr. Susan Branford
      • Pr Tim Hughes
      • Dr. David T. Yeung
      • Dr. Liu Lu
      • Dr. Naranie Shanmuganathan
      • Dr. Anthony P Schwarer
  • Medical Concepts
    • Introduction to CML >
      • Precision medicine in chronic myeloid leukemia
      • Philadelphia chromosome
      • BCR-ABL Transcripts
      • Sokal, Hasford, and EUTOS scores
    • General concepts >
      • Blood
      • Bone Marrow
      • DNA
      • Stem Cells
      • Immune System >
        • Natural killer cell - NK
        • T Cells
      • Blood-Brain Barrier
    • Clinical Trials
    • Treatment response in CML
    • Resistance to treatment in CML >
      • Molecular monitoring in CML >
        • Polymerase Chain Reaction
        • Dr. Kary Bank Mullis
      • Non-adherence of CML patients
      • Sensitive detection of BCR-ABL1 mutations
      • JAK2 Gene
    • Donor lymphocyte infusion (DLI)
    • Interferon regulatory factor 8 (IRF8)
    • Myeloproliferative disorders (MPD) >
      • Introduction to CML
      • Essential Thrombocythemia (ET)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
    • Types of leukemia >
      • Atypical chronic myeloid leukemia
  • Medication
    • Hydroxyurea
    • Interferon Alpha
    • Gleevec (Imatinib) >
      • Generic Imatinib
    • Tasigna (Nilotinib) >
      • Generic nilotinib
    • Sprycel (Dasatinib) >
      • Generic Dasatinib
    • Bosulif (Bosutinib)
    • Iclusig (Ponatinib)
    • Supect (Radotinib)
    • ABL001 (Asciminib)
    • Synribo (Omacetaxine )
    • Jakafi (Ruxolitinib)
    • Flumatinib
    • (Bafetinib)
    • (Danusertib)
    • (Rebastinib)
    • BGB324
    • PF-114
    • NEV-801
    • BP1001
    • HQP1351 (Olverembatinib)
    • K0706
    • ​ S116836
    • Vidaza (Azacitidine)
  • Managing side effects
    • List of side effets >
      • Bone Pain
      • Depression
      • Eyes
      • Ear
      • Fatigue
      • Fluid Retention
      • Gastrointestinal system
      • Hair
      • Heart
      • Hepatotoxicity
      • Kidney
      • Muscle cramping
      • Peripheral Neuropathy in CML
      • Peripheral arterial disease in CML
      • Pleural effusion
      • Pulmonary arterial hypertension
      • Thyroid dysfunction
      • Skin
      • Weight gain
    • CML and Nutrition
    • Food and Drug Interactions
    • Living with CML and diabetes
    • CML and comorbidities
    • Psycho-Oncology
    • Complementary and Alternative Medicine >
      • Art Therapy >
        • Art Therapist
        • CMLer's portofolio
      • Music therapy >
        • YouTube creation by CMLer's family
        • Relaxing Music for Stress Relief. Calm Music for Meditation, Sleep, Healing Therapy, Spa
        • Debussy – Relaxing music - Clair de lune et autres...
        • Delicate music for the soul and LIFE, and birdsong soothes the nervous system.
        • Adagio for Strings (Samuel Barber)
        • Amélie Soundtrack ♥ Comptine d'Un Autre Été
      • Yoga
      • Physical Activity
      • Zootherapy
  • Patient Testimonials
    • 30 years and plus survivors >
      • Mark Popadick
      • Mary Sullivan
      • Tom Strodl
      • Dr. Robert Patenaude -E
      • Skip Duffe
    • 20 years and plus survivors >
      • Doug Jenson
      • Joannie Clements
      • Mel Mann
      • Kevin Williams
      • Rich Jones
      • Tanja Fajon
      • Tamera Simonson
      • Virginia Garner
    • 10 years and plus survivors >
      • Jan Geissler
      • Mary Jane Bertram
      • Pat Elliott
      • Tegan Kubler
      • Jo'story
      • Rob Shick
      • Gary Gonzales
      • Hans Loland
      • Drew Johnston
      • Erin Havel (Author)
      • Sohag
      • Erin Zammett Ruddy
      • Kayla Naton (Pregnancy)
      • Jean McGlynn
      • Tom Cleaver
    • New CMLers >
      • Skye Davidson
      • Amanda Steffy
      • Abbi Evans
      • Alyssa
      • Austin Granatowicz
      • Brown Dudley
      • Nigel
      • Katie
      • Kris
      • Ron Robbecke
    • Some celebrities >
      • How to get the password?
      • Alexa Score
      • Laura Boyd
      • Dr. Richard Rockefeller
      • Ryan O'Neal
      • Tim Holcomb
      • Doris Muramatsu
      • Charlie Schlatter
      • Kareem Abdul-Jabar
      • Kelvin Alston
      • Carlos Carrasco
      • Jason Blake
      • Brian Boyle
      • Roman Reigns
      • Rick Upchurch
    • Suzan Mc Namara and the petition
    • Bud Romine - the first patient
    • Other testimonials
    • Blogs >
      • Blog recently updated >
        • Access CML Drugs
        • Living with CML
        • Michelle D's Blog
        • Jon's Blog
        • Justin Ozuna's Blog
        • Trey's CML Leukemia Blog
      • Blog not recently updated >
        • CMKID's blog – Dislodging the bullet - 2012
        • CML Recovery - Stopping KTI -2011
        • Hans's Blog -2012
        • Elizabeth's Blog - my leukemia - 2013journey
        • Elizabeth's Blog - Heart of the rose -2011
        • Joe's Blog - 2012
        • Josh's Blog - 2014
        • Mannan's Blog -2014
        • Ian's Blog -2014
        • Matt's Blog - 2012
        • Matthew's Blog - 2014
        • Michelle's Blog -2012
        • Nayree's Blog -2011
        • Rob's Blog - 2011
  • Global News on CML
    • English - Latest CML News >
      • News -Archives 2019-2018
      • News - Archives 2017-2016
      • News Archives - 2015-2014
      • News-Archives -2013-2012
      • News - Archives 2011-2001
    • French (Français) - Dernières nouvelles
    • Spanish (Español)-Ultimas noticias
  • Links to other sites, forums and Facebook
    • Sites ( English and other languages)
    • Forums (English and other languages)
    • CML on Facebook (English and other languages)
    • CML on Twitter
    • Audio Podcast
  • Various topics
    • CML patients and the coronavirus
    • You’ve just been diagnosed
    • CML causes
    • Pronostic, life expectancy, quality of life, ..... in chronic myeloid leukemia
    • Increased Risk of Secondary Cancers with CML
    • Vaccination of CMLers
    • CML and pregnancy
    • Children with CML
    • Elderly patients with CML
    • Bone marrow transplant
    • Stem cells from umbilical cord blood
    • CML Blast Crisis treatment
    • Mutation T315I
    • Sports with CML
    • History of CML
    • CML Awareness Day
    • The movie "Dying to Survive"
  • Cure possible for CML?
    • Hematopoietic stem cell transplantation using single UM171-expanded cord blood
    • Combination of tyrosine kinase inhibitor with other medication >
      • Combinaison of hydroxychloroquine with tyrosine kinase inhibitor
      • Combination of ruxolitinib with tyrosine kinase inhibitor
      • Combination of miristen with tyrosine kinase inhibitor
      • Combination of pioglitazone with tyrosine kinase inhibitor
      • Combination of Inecalcitol with tyrosine kinase inhibitor
      • Combination of dasatinib plus Nivolumab
      • Combination of Pembrolizumab with tyrosine kinase inhibitor
      • Combination of interferon with tyrosine kinase inhibitor
      • Combination of Venetoclax with tyrosine kinase inhibitor
    • Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells
    • Inhibition of the protein Ezh2 can cure CML?
    • Inhibition of STAT5 in conjunction with standard TKI therapy
    • PROTAC-mediated Targeted Protein Degradation
    • CML vaccine
    • Can immunotherapy cure leukemia?
    • Could fasting cure chronic myeloid leukemia
    • Chimeric Antigen Receptor T-Cell Therapy
    • Can genetic sequencing help to cure leukemia?
    • Can the new drug CX-5461 cure leukemia?
    • CRISPR-Cas9 gene-editing technique
    • Presence of bcr abl fusion transcripts in healthy individua
    • Math could help cure leukemia
    • Natural Medicine >
      • Possible cure for CML in Fish Oil
      • Betel leaf may help fight CML
      • Feverfew extract (parthenolide)
      • Can dandelions kill cancer?
      • Can curcumin cure leukemia?
  • Treatment free remission(TFR)
    • The French trial called STIM (Stop Imatinib)
    • De-escalation of treatment
    • Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients
  • Educational videos
    • Educational videos (in English)
    • Educación de vídeos en español (in Spanish)
    • Vidéos pédagogiques en français (in French)
  • Educational events
  • CML Glossaries
  • Moral Support
    • Where to get help and support
    • Family support
    • Dances at the Cancer Research Centre
    • I Had Cancer: You are not alone
    • I’m A Doctor With Chronic Illness. Here Are 12 Things I Wish People Knew
    • 23 Nice Things You Can Do for Someone With Cancer
    • Stronger
    • The march toward healing
    • Be happy
  • Congresses, conferences, meetings ASH, ASCO, EHA ...
    • ASCO - American Society of Clinical Oncology >
      • ASCO 2020 - Chicago
      • ASCO 2019 - Chicago
      • ASCO 2018 - Chicago
      • ASCO 2017 - Chicago
      • ASCO 2016 - Chicago
      • ASCO 2015 - Chicago
      • ASCO 2014 - Chicago
      • ASCO 2013 - Chicago
      • ASCO 2012 - Chicago
      • ASCO 2011 - Chicago
      • ASCO 2010 - Chicago
    • ASH - American Society of Hematology >
      • ASH 2020 - Virtual
      • ASH 2019- Orlando
      • ASH 2018 - San Diego
      • ASH 2017 - Atlanta
      • ASH 2016 - San Diego
      • ASH 2015 - Orlando
      • ASH 2014 - San Francisco
      • ASH 2013 - New Orleans
      • ASH 2012 - Atlanta
      • ASH 2011 - San Diego
      • ASH 2010 - Orlando
      • ASH 2009 - New Orleans
    • BTG - Bridging the Gap >
      • BTG2019 - Fuzhou - China
      • BTG2018 - Seoul, Korea (South)
      • BTG 2011 - Singapore (Singapore)
    • CML & MPDs - UK National Meetings
    • CML Horizons >
      • CML Horizon 2019 - Lisbon - Portugal
      • CML Horizon 2018 -Warsaw (Pologna)
      • CML Horizon 2017- Frankfurt (Germany)
      • CML Horizon 2016 - Ljubljana (Slovenia)
      • CML Horizons 2015 - (Barcelona, Spain)
      • CML Horizons 2014 - ( Belgrade, Serbia)
      • CML Horizons 2013 - (Prague - Czech Republic)
      • CML Horizons 2012 - (Munich, Germany)
      • CML Horizons 2011 - (Amsterdam - The Netherlands)
    • EHA - European Hematology Association >
      • EHA 2020 - Frankfurt,Germany(
      • EHA 2019 - Amsterdam (Netherlands)
      • EHA 2018 - Stockholm(Sweden)
      • EHA 2017 - Madrid (Spain)
      • EHA2016-Copenhagen,(Denmark)
      • EHA 2015 - Vienne (Austria)
      • EHA 2014 - Milan (Italy)
      • EHA 2013 - Stockholm (Sweden)
      • EHA 2012 - Amsterdam (The Netherlands)
      • EHA 2011 - London (England)
      • EHA 2010 - Cascais (Portugal)
      • EHA 2009 - Berlin (Germany)
      • EHA 2008 - Copenhague (Danemark)
    • ESH - European School of Haematology >
      • ESH 2020 - Mandelieu-La Napoule, -France
      • ESH 2019 - Bordeaux - France
      • ESH 2016 - Houston - USA
      • ESH 2015 - Estoril - Portugal
      • ESH 2014 - Philadelphia
  • Professionnel help and literature
    • Dr. Siddhartha Mukherjee
  • Patient Rights
  • New technological advances
  • International publications
    • Publications from Africa
    • Publications from America
    • Publications from Australia
    • Publications from Asia
    • Publications from Europe
  • Specialist Journals in Hematology/Oncology
  • Foundations
    • Leukemia Foundations >
      • American Cancer Society
    • Hospital Foundations
  • Awards & Recognition
  • Private group registration
    • Membership registration - CMLeukemia private group
    • Enregistrement des membres - Groupe privé CMLeukemia
    • Registro de membresía - CMLeucemia grupo privado
  • DONATE
  • About us
    • Our mission
    • Total access on the website - membership
  • Contact us
Chronic Myeloid Leukemia

Iclusig® (Ponatinib) - Chronic Myeloid Leukemia - CML

 
"Ponatinib (trade name Iclusig /aɪˈkluːsɪɡ/ eye-KLOO-sig, previously AP24534) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor.[2] Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors.[3]
The United States Food and Drug Administration approved the drug as a candidate in December 2012, but temporarily suspended sales on 31 October 2013 because of "the risk of life-threatening blood clots and severe narrowing of blood vessels".[4][5] This suspension was partially lifted on Dec. 20, 2013 with ponatinib being issued revised prescribing information, a new "Black Box Warning" and a "Risk Evaluation and Mitigation Strategy" in place to better evaluate the risks and benefits of using the drug."
Extract of wikipedia

​See also the List of side effects 
​
SITES
​

Iclusig®(Ponatinib) - Ariad
FORUMS
Ponatinib on Facebook


BLOGS
Hans’s Blog
CLINICAL TRIALS

Ponatinib for CML Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) (PACE)

Expanded Access Program of Ponatinib

A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia (OPTIC-2L)

​Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias or Solid Tumors

Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

                           All clinical trials with ponatinib
VIDEOS

Jorge E. Cortes, MD, on Chronic Phase CML: Comparing Three Starting Doses of Ponatinib
June 11-21, 2020, The ASCO Post

​

FLAG-IDA and ponatinib in blast phase CML: MATCHPOINT trial
January 24, 2020, VJHemOnc – Video Journal of Hematological Oncology

Dose-Related Adverse Events With Ponatinib When Treating CML
July 29, 2019, Targeted Oncology

Bosutinib Versus Ponatinib in R/R CML
July 22, 2019, Targeted Oncology

Early Intervention With Ponatinib in Treatment of CML
July 17, 2019, Targeted Oncology

Case 2: Ponatinib for T315I-Mutated CML
June 4, 2019, Targeted Oncology


Rationale for TKI Therapy in Relapsed CML
January 22, 2018, Targeted Oncology

Using ponatinib to treat highly resistant chronic myeloid leukemia, results from a Phase I trial
January 10, 2017,   VJHemOnc 
​
Modelling ponatinib resistance in BCR-ABL1 cell lines
August 3, 2016, ecancer


What are the efficacy and safety considerations in using ponatinib?
April 29, 2016, MediCom Oncology


Management of Thrombosis Risk with Ponatinib and other TKIs for CML?
May 15, 2015, ImedexCME

Epic:Phase 3 Trial of Ponatinib Compared with Imatinib in Newly Diagnosed Chronic Myeloid Leukemia
February 16, 2015, Oncology.TV

Treatment Selection for Resistant or Intolerant Chronic Myeloid Leukemia
February 24, 2014, OncLiveTV


More on Ponatinib and Next Steps - Harry  Erba, MD      
November 7, 2013, NationalCMLSociety

Considerations for Patients Taking Ponatinib - Michael Mauro, MD           
November  5, 2013, NationalCMLSociety·


Dr. Jorge Cortes Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial             
June 14, 2012, OncLive

ARIAD: Xiaotian Zhu on Ponatinib                                                                  
April 3, 2012, Executive video  
   

ARTICLES

FDA Approves Ponatinib To Treat Adult Patients with Resistant/Intolerant Chronic-Phase CML
December 18, 2020, Cancer Network

Ponatinib Demonstrates Efficacy Over Time for Patients With CP-CML After Prior TKI Failure
December 7, 2020,  Targeted Oncology

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic
December 7, 2020, ASH 2020

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML
December 7, 2020, ASH 2020

Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance
September 28, 2020, PubMed

Ponatinib starting dose may be linked to efficacy, safety in chronic-phase CML
September 15, 2020, Healio

Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia
February 11, 2020, Blood Advance 
​
Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management
October 7, 2019, Acta Haematologica

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
September 4, 2019, PubMed

Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity
April 2019,  Hong Kong Medical Journal

Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation
March 16, 2019, PubMed

Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors
November 29, 2018, Blood

Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
October 15, 2018, Cancer Therapy Advisor

Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study
May 7, 2018, PubMed

Analyst 'would not be surprised' to see Takeda retry Iclusig in first-line CML
March 25, 2018,   The Pharma Letter  

Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal Phase 2 PACE Trial in Blood
March 22, 2018,  Boston Business Journal

Publication of Final Data from ICLUSIG (ponatinib) Pivotal Phase 2 PACE Trial
March 22, 2018, Drug Discovery & Development

Ponatinib Maintains Benefit in Chronic-Phase CML at 5 Years
March 22, 2018, OncLive

Ponatinib Shows Promise for Rare Ovarian Cancer Type that Affects Young Women
March 8, 2018,  Oncology Nursing News

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study
December 2017,  ASH 2017
 
A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy
December 2017, ASH 2017

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
December 2017, ASH 2017

A Real Life Evaluation of Efficacy and Safety of Ponatinib Therapy  in CML Patients
​
​​December 2017, ASH 2017

Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting
October 2017, PublMed

Ponatinib: Black Box Warning and Drug Interactions
January 17, 2017,  Cancer Therapy Advisor

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
April 14, 2016, NCBI

Ponatinib and Cardiovascular Complications
December 4, 2016, ASH 2016

Ponatinib in Chronic-Phase Chronic Myeloid Leukemia Patients: Final Report from a Phase 1 Trial
December 4, 2016, ASH 2016

Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation
December 4, 2016, ASH 2016

Imatinib as Second-Line Therapy, Ameliorates or Maintains Molecular Responses Obtained with Ponatinib First-Line in Chronic Phase CML Patients
December 3, 2016, ASH 2016

Ponatinib Approved for CP-CML Not Indicated for Prior TKI
December 1, 2016,  Cancer Therapy Advisor

Response Rate Similar Between Low- and Standard-dose Ponatinib
September 23, 2016, Cancer Therapy Advisor

Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase
June 2016, Haematologica

ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
June 13, 2016, Business Wire

Vascular Events Remain Problem for Ponatinib in CML
Apr 22, 2016‎, Cancer Network

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
April 14, 2016, NCBI

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
April 12, 2016, NCBI

Ponatinib vs Allogeneic SCT Promising for T315I Mutation-positive CP-CML
January 11, 2016, Cancertherapyadvisor

Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON)
June 2015,  2015 ASCO Annual Meeting 

Elevated blood pressure (BP) and adverse events (AEs) of hypertension (HTN) in ponatinib (PON) leukemia trials.
June 2015,  2015 ASCO Annual Meeting 

Efficacy and safety of ponatinib in heavily pretreated leukemia patients in the PACE trial: 3-year results.
June 2015,  2015 ASCO Annual Meeting     

Long-term Bosutinib in patients with chronic phase  CML after prior  imatinib failure
June 2015,  EHA 2015  

Ponatinib efficacy and safety in heavily pretreated leukemia patients: 3-year results of the Pace trial 
June 2015,  EHA 2015   

Ponatinib efficacy and safety in heavily pretreated leukemia patients: 3-year results of the Pace trial 
June 2015,  EHA 2015  

Long-term follow-up of ponatinib effivacy and safety in patients (PTS) with the T315I mutation in the phase 1 and phase 2(pace) trials.
June 2015,  EHA 2015

Elavated  Blood Pressure  ans adverse events of hypertension  in phase 1,2 and 3 trials of ponationib in leukemia
June 2015,  EHA 2015  

T315I clone selectioin in a PH+ All patient under maintenance Ponatinib
June 2015,  EHA 2015

Hematologic safety data of single-agent ponatinib from a phase I and phase II trial in Philadelphia chromosome-positive (Ph+) CML/ALL patients
June 2, 2014, 2014 ASCO Annual Meeting

Longer-term follow up of a phase 1 study of ponatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias
June 2, 2014, 2014 ASCO Annual Meeting

EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML
May 31, 2014, 2014 ASCO Annual Meeting

ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Australia
January 28, 2014, Business Wire

Patients'  advocates press FDA to retain lifesaving drugs  (Iclusig)
November 24, 2013, Boston  Globe

Ariad jumps on  European drug action 
November 23, 2013,
Boston  Globe

European Medicines Agency recommends  changes in use of leukaemia medicine Iclusig (ponatinib) in order to minimise
risk of blood clots

November 22, 2013,  European Medicine  Agency

Ponatinib demonstrated activity in  patients with CML, Ph+ALL
November 21, 2013, HemOnctoday

PRAC updates on the risks of serious  vascular occlusive events associated with cancer medicine Iclusig
November 8, 2013, European Medicines  Agency

Doctors Fear  Losing Leukemia Drug Deemed Risky
November 1, 2013, New York Times

The Leukemia  & Lymphoma Society  Issues Statement  Regarding the Status of Iclusig
November 1, 2013, DigitalJournal.com

Serious Danger  of Blood Clots  Halts Sale of Leukemia Drug
October 31, 2013,  New York  Times

Genetic details  of leukemia resistance
October 31, 2013, Oncology Nurse  Advisor

Ariad announces  discontinuation of a trial for its leukemia  drug
October 18, 2013, boston.com

Ariad crushed  (again) after PhIII Iclusig trial is shuttered on blood clot  fears
October 18, 2013, FierceBiotech
 
Ariad Stops  Phase 3 Epic Trial Of Iclusig In Patients With Newly Diagnosed  CML
October 18, 2013, RTT  News

Safety Concerns Halt Ponatinib  Development
October 9, 2013, Onc  LIve

Ponatinib—A Step Forward in Overcoming  Resistance in Chronic Myeloid Leukemia
August 5, 2013, Clinical cancer  Research

Effects of food on the pharmacokinetics  of ponatinib in healthy subjects.
July 25, 2013,  PublMed

New TKI Ponatinib Effective in Resistant  CML
February  2013, Clinical Oncology  News

Ponatinib Could Herald “Revolution”in CML  Treatment
December 20, 2012, OncLive

Ponatinib in Refractory Philadelphia  Chromosome–Positive  Leukemias
November 29, 2012, The  New England  Journal of Medicine

F.D.A. Gives Early Approval to Drug for Rare Leukemia
December 14, 2012,  The New York  Times

OHSU-developed ponatinib wins FDA  approval
December 14, 2012, Portland Business  Journal

FDA grants approval for potential  ‘blockbuster’ leukemia drug made by Cambridge-based Ariad
December 14, 2012, Boston.com

ARIAD Announces Accelerated Approval by FDA of Iclusig (Ponatinib) for Patients with CML and Ph+ ALL Resistant or Intolerant to Prior Tyrosine Kinase Inhibitor Therapy
December 14, 2012, Fierce Biotech
 
FDA Approves Ariad Pharma Leukemia  Drug
December 14, 2012, The Street

Ponatinib  offers new hope in drug-resistant leukemia
December 5, 2012 , News-Medical.net

 
Chronic Myeloid Leukemia Mutation Thwarted By Ponatinib
December 2, 2012,  Science  2.0

Data Published on ARIAD Candidate - Analyst  Blog
November 30, 2012, Nasdaq

In CML, Next-Generation TKIs Aim to Boost  Outcomes
November 30, 2012, Onc  LIve

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia
November 29, 2012, News Medical

Ponatinib for Chronic Myeloid Leukemia
November 29, 2012, The New England  Journal of Medicine

Ponatinib acts against the most resistant types of chronic myeloid leukemia
November 28, 2012, Science Codex

Ponatinib Acts Against the Most Resistant Types of Chronic Myeloid Leukemia
November 28, 2012, Science Daily

FDA Agrees to Speed Review of Ariad Drug
October 25, 2012, DailyFinance

Ariad Pharmaceuticals: Ponatinib Approval Anticipated In Second-Line CML
October 1, 2012, Seeking Alpha

ARIAD Announces Submission of Marketing Authorization Application for Ponatinib to the European Medicines Agency
August. 30, 2012, Fierce Pharma.

Ariad Pharmaceuticals Gearing Up For Ponatinib's Approval
August 29, 2012, Seeking  Alpha

ARIAD Pharma initiates phase I/II trial of ponatinib in Japan
August 22, 2012, Pharmabiz.com

Accelerated FDA Approval for CML Drug Ponatinib Sought
August 9, 2012, Cancer Network

Ponatinib Achieves Primary Endpoints in CML Subtypes
August 8, 2012, OncLive

Ariad Prepares for Early Launch of CML Drug Ponatinib
August 6, 2012, Oncology Stat

Ariad speeds targeted leukemia drug to FDA in race for key approval
July 31, 2012, FierceBiotech

Ariad Pharma ANNOUNCES Phase 3 Trial and 4 Stocks Hitting 52-Week Highs
July 28, 2012, Wall St . Cheqt  Sheet

Platelet dysfunction associated with ponatinib, a new  pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to  multiple tyrosine kinase inhibitor therapy
April 24, 2012, Haematologica
Ponatinib Continues to Impress in Patients with Leukemia
February 15, 2012, The ASCO Post ​


Ariad Pharmaceuticals Still Might Have Upside
December 21, 2011, Investor Place

Ariad's ponatinib takes center stage with promising pivotal leukemia data
December 12, 2011, Fierce Biotech

Drug For Chronic Myeloid Leukemia To Be Out Soon
December 12, 2011, TopNews

Initial Findings from the PACE trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+All
Resistant or Intolerant or Dasatinib or Nilotinib, or with the T315I  Mutation

December 2, 2011, Ariad

Ariad Pharma: Early Efficacy, Safety of Leukemia Drug 'Striking'
November  7, 2011, The Street

ARIAD Presents New Preclinical Data On Ponatinib In Solid Tumors, Demonstrating Inhibition Of All FGF Receptor Kinases
April 6, 2011,  Business Wire

Phase I Trial Shows Ponatinib May Thwart Most Resistant CML
December 16, 2010,  MD Anderson Cancer Center -  Department of Leukemia

Updated Phase 1 study data of ponatinib in  patients with refractory CML, Ph+ ALL presented at ASH
December 6, 2010 , News medical

Novel CML Drug Active After Failures of Imatinib, Dasatinib, and Nilotinib
December 6, 2010, Oncology Stat

Phase I Trial Indicates Ponatinib May Thwart Most Resistant CML
December 2010, Drugs.com
 
ARIAD Announces Initiation Of Ponatinib (AP24534) Pivotal Trial In Drug-Resistant Or Intolerant Chronic Myeloid Leukemia
September 2010, Fierce Biotech

Phase 2 trial of ponatinib for the treatment of chronic myeloid leukemia (CML) and  Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL)
September 2010, MPR


          (See our disclaimer - Voir notre avis de non-responsabilité- Vea nuestro descargo de responsabilidad)
​
        Privacy Policy   
                    
Copyright © 2010-2021 CMLeukemia.com
Protected by Copyscape     DMCA.com Protection Status